Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
View original at globenewswire.comZentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedb…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Azenosertib is a potentially first-in-class and best-in-class WEE1 inhibitor
80% confidenceCompany expects to disclose topline data from DENALI Part 2 by year end 2026
80% confidenceFurther development in USC will be limited to partnering or the Company's ability to allocate capital to this indication
80% confidenceResults from the TETON trial are planned for publication in the first half of 2026
80% confidenceDENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review
80% confidenceDENALI clinical trial remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback
80% confidenceIn clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types
80% confidence$280.7 million in cash provides runway into late 2027
80% confidenceExisting cash, cash equivalents and marketable securities as of September 30, 2025 will be sufficient to fund operating expenses requirements into late 2027
80% confidence